Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: TQJ230
  • drug: Placebo

Eligibility


Key Inclusion Criteria

   - Lp(a) ≥ 70 mg/dL at the screening visit, measured at the Central laboratory

   - Myocardial infarction: ≥ 3 months from screening and randomization to ≤ 10 years prior
   to the screening visit

   - Ischemic stroke: ≥ 3 months from screening and randomization to ≤ 10 years prior to
   the screening visit

   - Clinically significant symptomatic peripheral artery disease

Key Exclusion Criteria

   - Uncontrolled hypertension

   - Heart failure New York Heart Association (NYHA) class IV

   - History of malignancy of any organ system

   - History of hemorrhagic stroke or other major bleeding

   - Platelet count ≤LLN

   - Active liver disease or hepatic dysfunction

   - Significant kidney disease

   - Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply at the end.

Ages Eligible for Study

18 Years - 80 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting